UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000024227
Receipt number R000027897
Scientific Title Safety and efficacy of Daclatasvir and Asunaprevir combination therapy for hemodialyzed patients with genotype 1 chronic hepatitis C infection
Date of disclosure of the study information 2016/09/29
Last modified on 2022/10/06 09:55:21

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Safety and efficacy of Daclatasvir and Asunaprevir combination therapy for hemodialyzed patients with genotype 1 chronic hepatitis C infection

Acronym

Daclatasvir and Asunaprevir therapy for hemodialyzed ptatients

Scientific Title

Safety and efficacy of Daclatasvir and Asunaprevir combination therapy for hemodialyzed patients with genotype 1 chronic hepatitis C infection

Scientific Title:Acronym

Daclatasvir and Asunaprevir therapy for hemodialyzed ptatients

Region

Japan


Condition

Condition

hemodialyzed patients with genotype 1
chronic hepatitis C infection

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To analyze Safety and efficacy of Daclatasvir and Asunaprevir combination therapy for hemodialyzed patients with chronic hepatitis C infection

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Sustained virological response
adverse events

Key secondary outcomes



Base

Study type

Others,meta-analysis etc


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

hemodialyzed patients with genotype 1 chronic hepatitis C, who initiated on dacalatasvir and asunaprevir between November 2014 and march 2016

Key exclusion criteria

1patients with heart failure
2patients with decompensated cirrhosis
3patients with allergic to NS5A inhibitor or HCV PI inhibitor
4 patients with HCC or other malignant disease

Target sample size

130


Research contact person

Name of lead principal investigator

1st name Goki
Middle name
Last name Suda

Organization

Graduate School of Medicine,Hokkaido University

Division name

Department of Gastroenterology and Hepatology, Graduate School of Medicine

Zip code

065-0010

Address

Kita 14-jo Nishi 5-jo, Kita-ku, Sapporo city, Hokkaid

TEL

011-716-1161

Email

gsudgast@pop.med.hokudai.ac.jp


Public contact

Name of contact person

1st name Goki
Middle name
Last name Suda

Organization

Hokkaido University

Division name

Department of Gastroenterology and Hepatology, Graduate School of Medicine,

Zip code

065-0010

Address

Kita 14-jo Nishi 5-jo, Kita-ku, Sapporo city, Hokkaid

TEL

011-716-1161

Homepage URL


Email

gsudgast@pop.med.hokudai.ac.jp


Sponsor or person

Institute

others

Institute

Department

Personal name



Funding Source

Organization

self funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

IRB committee of Hokkaido University Hospital

Address

Sapporo city kita ku kita14zyou nishi 5

Tel

0117067061

Email

crjimu@huhp.hokudai.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 09 Month 29 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 09 Month 29 Day

Date of IRB

2016 Year 09 Month 29 Day

Anticipated trial start date

2016 Year 09 Month 29 Day

Last follow-up date

2019 Year 09 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Safety and efficacy of Daclatasvir and Asunaprevir combination therapy

Observation and Test Parameters and Methods
The following items will be checked.
Patient characteristics: gender, age, height, liver histology, prior treatments, allergic history, medical history, and any complications Hematological parameters
1Viral factors: HCV NS5A/NS3 inhibitor resistant mutations
2Peripheral blood tests: WBC, differential WBC, Hb, and Plt
3Liver function tests: AST, ALT, GTP, and ALP
4Biochemistry: LDH, BUN, total bilirubin, direct bilirubin, ALP, total protein, albumin, creatinine, Na, K, Cl, amylase, and lipase
5Fibrosis markers: hyaluronic acid, type IV collagen, and AFP
6Glucose tolerance tests:fasting glucose, insulin, and HbA1c; Lipid metabolism: TC, LDL-C, and TG; Blood coagulation: PT-INR
7Viral kinetics: serial measurement of viral load (Taqman-PCR assay)
8IL28B,
9Measurement of liver stiffness by liver biopsy/FibroScan


Management information

Registered date

2016 Year 09 Month 29 Day

Last modified on

2022 Year 10 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027897


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name